Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

Prostate

Volumn 29, Issue 6, 1996, Pages 371-380

  Murphy, Gerald P ^a   Tjoa, B ^a   Ragde, H ^a   Kenny, G ^a   Boynton, A ^a  

^a NORTHWEST HOSPITAL   (United States)

Author keywords

dendritic cells (DC); immunotherapy; Phase I trial; prostate cancer; T cell

Indexed keywords

HLA ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

DENDRITIC CELLS; HLA-A ANTIGENS; HUMANS; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INCIDENCE; INTERFERON-ALPHA; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030470404     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199612)29:6<371::AID-PROS5>3.0.CO;2-B     Document Type: Article

References (27)

1. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453-1457, 1992.
2. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/ neu-derived peptide. Proc Natl Acad Sci USA 92:432-436, 1995.
3. Ioannides CG, Fisk B, Pollack M, Frazier ML, Wharton JT, Freedman RS: Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones. J Immunol 37:413-424, 1993.
4. Urban JL, Schreiber H: Tumor antigens. Annu Rev Immunol 10:617-644, 1992.
5. VanderBruggen P, Traversari C, Chomez P, Lurquin C, DePlaen E, VanderEynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647, 1991.
6. Zinkernagel RM, Doherty PC: Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248:701, 1974.
7. Engelhard VH: Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol 12:181-207, 1994.
8. Falk K, Rotzchke O, Stevanovic S, Jung G, Rammensee HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351: 290-296, 1991.
9. Grey HM, Ruppert J, Vitiello A, Sidney J, Kast WM, Kubo RT, Sette A: Class I MHC-peptide interactions: Structural requirements and functional implications. Cancer Surv 22:37-49, 1995.
10. Ruppert J, Sidney J, Cells E, Kubo R, Grey H, Sette A: Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929-937, 1993.
11. Tsuji K, Aizawa M, Sasazuki T: Allele frequencies, Section 6.3: Splits combined (five loci). In "Proceedings of the the Eleventh International Histocompatibility Workshop and Conference," Nov. 6-13: 1991, Yokohama, Japan. Tokyo: Oxford University Press, pp 1066-1077, 1992.
12. Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G: Presentation of Prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28:65-59, 1996.
13. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostate cells and serum of prostatic cancer patients. Anticancer Res 7:927-936, 1987.
14. Israeli RS, Powell CT, Corr JG, Fair WR, Heston DW: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 54: 1807-1811, 1993.
15. Murphy G, Ragde H, Kenny G, Barren R III, Erickson S, Tjoa B, Boynton A, Holmes E, Gilbauch J, Douglas T: Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res 15:1473-1480, 1995.
16. Murphy GP, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, Barren RJ III: Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunoabsorbent assays in prostatic cancer patients. Prostate 26: 164-168, 1995.
17. Knight SC, Stagg AJ: Antigen-presenting cell types. Curr Opin Immunol 5:374-382, 1993.
18. Grabbe S, Beissert S, Schwartz T, Granstein RD: Dendritic cells as initiators of tumor immune response: A possible strategy for immunotherapy? Immunol Today 16:117-121, 1995.
19. Steinman RM: The Dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296, 1991.
20. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118, 1994.
21. Tjoa B, Erickson S, Barren R III, Ragde H, Kenny G, Boynton A, Murphy G: In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 27:63-39, 1995.
22. Freudenthal PS, Steinman RM: The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci USA 87: 7698, 1990.
23. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93, 1994.
24. Berhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA: Generation of immunostimulatory dendritic cells from human CD34+ hematopoetic progenitor cells of the bone marrow and peripheral blood. Cancer Res 55:1099-1104, 1995.
25. Parham P, Brodsky FM: Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 3:277-299, 1981.
26. Murphy GP, Barren RJ, Erickson SJ, Bowes VA, Wolfert RL, Bartsch G, Klocker H, Pointner J, Reissigl A, McLeod DG, Douglas T, Morgan T, Kenny GM, Ragde H, Boynton AL, Holmes EH: Evaluation and comparison of two new prostate carcinoma markers: Free-prostate specific antigen and prostate specific membrane antigen. Cancer 78:809-818, 1996.
27. Thom A, Alexander H, Andrich M, Barker W, Rosenberg S, Fraker D: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 13:264-273, 1995.